β-tubulin III and IV expression as predictive factors for overall survival after paclitaxet therapy in patients with heavily pre-treated metastatic breast cancer.

被引：0
|
作者：
Kendzierski, N.
Mangia, A.
Ulbrich, E. J.
Strauss, H. G.
Thomssen, C.
Paradiso, A.
机构：
[1] Univ Halle Wittenberg, Halle, Germany
[2] Natl Canc Inst, Bari, Italy
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [21] Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
    Miller, KD
    Weathers, T
    Haney, LG
    Timmerman, R
    Dickler, M
    Shen, J
    Sledge, GW
    ANNALS OF ONCOLOGY, 2003, 14 (07) : 1072 - 1077
  • [22] Fulvestrant in heavily pre-treated ER-positive post-menopausal metastatic breast cancer patients: final update of a phase II study
    Ratti, R.
    Coccorullo, Z.
    Guarneri, D.
    Addamo, G.
    Colloca, G.
    Venturino, A.
    Campora, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 279 - 279
  • [23] Clinical activity and cardiac tolerability of metronomic non-pegylated liposomal doxorubicin in heavily pre-treated patients with metastatic breast cancer: A single institucion experience.
    Ingrid Rojas, Katerin
    Manso, Luis
    Manuel Sepulveda, Juan
    Mendiola, Cesar
    Pascual, Tomas
    Ciruelos, Eva
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
    Yadav, Madhav
    Ballal, Sanjana
    Bal, Chandrasekhar
    Tripathi, Madhavi
    Damle, Nishikant
    Shamim, Shamim Ahmed
    Kumar, Rakesh
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [25] Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2-metastatic breast cancer.
    Mayer, Erica L.
    Wander, Seth Andrew
    Regan, Meredith M.
    DeMichele, Angela
    Forero-Torres, Andres
    Rimawi, Mothaffar F.
    Ma, Cynthia X.
    Cristofanilli, Massimo
    Anders, Carey K.
    Bartlett, Cynthia Huang
    Winer, Eric P.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Sahoo, Ranjit Kumar
    Tripathi, Madhavi
    Damle, Nishikant Avinash
    Shamim, Shamim Ahmed
    Kumar, Rakesh
    Seth, Amlesh
    Bal, Chandrasekhar
    PLOS ONE, 2021, 16 (05):
  • [27] Outcomes of Everolimus plus Exemestane in ER-positive, HER2-negative Heavily Pre-treated Metastatic Breast Cancer Patients: A Real Life Multicentre Experience
    Desai, P.
    Hogg, M.
    CLINICAL ONCOLOGY, 2018, 30 (06) : E42 - E43
  • [28] Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing 177Lu-PSMA Therapy
    Ahmadzadehfar, Hojjat
    Essler, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (07) : 1033 - 1034
  • [29] Occult central nervous system (CNS) involvement in patients (pts.) with metastatic breast cancer: prevalence, predictive factors and impact on overall survival.
    Miller, KD
    Weathers, T
    Haney, LG
    Timmerman, R
    Dickler, M
    Shen, J
    Sledge, GW
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 240 - 240
  • [30] Prognostic factors predicting functional outcomes, recurrence-free survival, and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer patients
    Rades, D
    Veninga, T
    Stalpers, LJA
    Schulte, R
    Hoskin, PJ
    Poortmans, P
    Schild, SE
    Rudat, V
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (01): : 182 - 188
12345